EWTX - NASDAQ

Edgewise Therapeutics, Inc.

EWTX·NASDAQ

$36.21

-1.7%

HealthcareBiotechnology

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.90B

EPS-1.6300

P/E Ratio-22.21

Earnings Date08/06/2026

ewtx

Net Change in Cash

Last Annual Value

19.48M

3-Year CAGR

45%

5-Year CAGR

-25%

10-Year CAGR

Adjust for Inflation

Edgewise Therapeutics, Inc. Competitors Analysis of Net Change in Cash

EWTX · NASDAQ

Company	Net Change in Cash	CAGR 3Y	CAGR 5Y	CAGR 10Y
Edgewise Therapeutics, Inc. NASDAQ:EWTX	19.48M	-32.8%	N/A	N/A
uniQure N.V. NASDAQ:QURE	-78.69M	N/A	N/A	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	262.08M	414.1%	58.8%	N/A
Structure Therapeutics Inc. NASDAQ:GPCR	630.12M	82.5%	47.9%	N/A
Viridian Therapeutics, Inc. NASDAQ:VRDN	112.79M	N/A	N/A	N/A
Nuvation Bio Inc. NYSE:NUVB	128.36M	N/A	4.6%	N/A
Celldex Therapeutics, Inc. NASDAQ:CLDX	515.00K	-54.3%	N/A	N/A
Janux Therapeutics, Inc. NASDAQ:JANX	-378.27M	N/A	N/A	N/A
Ocular Therapeutix, Inc. NASDAQ:OCUL	344.96M	54.5%	N/A	66.1%

Edgewise Therapeutics, Inc. Fair Value Envelope

EWTX · NASDAQ

Our analysis suggests that EWTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $36.21, this represents a potential HIDDEN relative to our calculated worth for Edgewise Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $36.21

Related Guides

Blog Categories

Continue your EWTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.